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Background Carboxylated osteocalcin (Gla‐OC) participates in bone remodeling, whereas the
undercarboxylated form (Glu‐OC) takes part in energy metabolism. This study was undertaken to
compare the blood levels of Glu‐OC and Gla‐OC in nonobese, healthy obese, and prediabetic
volunteers and correlate it with the metabolic markers of insulin resistance and early markers
of inflammation.
Methods Nonobese (body mass index [BMI] <30 kg/m2; n = 34) and obese subjects (30 <BMI
<40 kg/m2; n = 98), both sexes, aged 25 to 65 years, were divided into healthy control, normal
weight subjects, healthy obese, and obese with biochemical markers of prediabetes. The sub-
groups with obesity and low or high Gla‐OC or Glu‐OC were also considered for statistical
analysis. After 2 weeks of diet standardization, venous blood was sampled for the determination
of Gla‐OC, Glu‐OC, lipid profile, parameters of inflammation (hsCRP, interleukin 6, sE‐selectin,
sPECAM‐1, and monocyte chemoattractant protein 1), and adipokines (leptin, adiponectin,
visfatin, and resistin).
Results Gla‐OC in obese patients was significantly lower compared to nonobese ones
(11.36 ± 0.39 vs 12.69 ± 0.90 ng/mL, P = .048) and weakly correlated with hsCRP (r = −0.18,
P = .042), visfatin concentration (r = −0.19, P = .033), and BMI (r = −0.17, P = .047). Glu‐OC
was negatively associated with fasting insulin levels (r = −0.18, P = .049) and reduced in predia-
betic individuals compared with healthy obese volunteers (3.04 ± 0.28 vs 4.48 ± 0.57, P = .025).
Conclusions Decreased blood concentration of Glu‐OC may be a selective early symptom of
insulin resistance in obesity, whereas the decreased level of Gla‐OC seems to be associated with
the appearance of early markers of low grade inflammation accompanying obesity.
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Osteocalcin (OC or bone Gla protein, BGP) and matrix Gla
protein (MGP) were the first members of the growing family of vitamin
K‐dependent carboxylated proteins synthesized outside the liver and
found not to be involved in coagulation.1 Osteocalcin is released intoe Creative Commons Attribution‐N
d and is not used for commercial
rch and Reviews Published by Joh
wileyonlinthe circulation when new bone is formed and is considered a marker
of bone turnover.2 It was later identified as being secreted under nor-
mal, nonpathological conditions. The mature OC protein is small (49
amino acids in humans) and contains 3 glutamate residues, which once
γ‐carboxylated are responsible for its binding to calcium and hydroxy-
apatite. In turn 2 conserved cysteine residues of this protein form theonCommercial License, which permits use, distribution and reproduction in any
purposes.
n Wiley & Sons Ltd.
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2 of 11 RAZNY ET AL.intramolecular disulfide bond, which contributes to stabilizing its
three‐dimensional structure upon binding of its γ‐carboxylated gluta-
mate (Gla) residues to calcium.3 The undercarboxylated OC (Glu‐OC)
does not appear to bind calcium but could be involved in interactions
with its recently identified G protein‐coupled receptor family C group
6 member A (GPRC6A).4 It has been demonstrated that it is expressed
in many tissues including: liver, skeletal muscle, brain, testis, bone and
pancreatic β‐cells.5–7 Gprc6a−/− mice have more white fat compared
with wild‐type (WT) animals. They are glucose intolerant, insulin resis-
tant, develop hepatic steatosis and have reduced testosterone levels.8
All these observations suggested that GPRC6A mediates metabolic
function of osteocalcin. Recent studies have shown that carboxylated
osteocalcin (Gla‐OC) interacts with hydroxyapatite crystals and
modulates its growth, whereas the Glu‐OC has a hormone‐like
function in energy metabolism, fertility and brain development.4,9–11
The administration of exogenous Glu‐OC into WT mice decreased
their fat mass and serum triglyceride (TG) levels. In white adipose
tissue, Glu‐OC inhibited the expression of lipolysis mediating genes:
triglyceride lipase (Tgl) and perilipin, but activated the expression of
adiponectin and its target genes.12 Osteocalcin affected the expres-
sion of Pgc1a, Nrf1, and Mcad ‐ genes implicated in energy consump-
tion and mitochondrial biogenesis in muscles,13 whereas in the brown
adipose tissue expression of genes involved in thermogenesis: Ucp1
and Pgc1a was increased.12 Osteocalcin was demonstrated to affect
glucose uptake in skeletal and vascular muscle cells.14 It has also
been reported that osteocalcin can directly modulate glucose trans-
port in adipocytes, suppress the secretion of proinflammatory cyto-
kines and induce the secretion of anti‐inflammatory cytokines as
adiponectin.15 Oury et al10 have recently demonstrated that
disrupting osteocalcin signaling leads to glucose intolerance in both
humans and mice, providing evidence that there is some similarity
between mouse and human OC in mediated pathways. Several
available papers present osteocalcin studies in humans.16–19 Patients
with type 2 diabetes have been reported to have a lower concentra-
tion of serum osteocalcin compared to healthy counterparts.17
Semenkovich and Teitelbaum18 suggested existing a cycle in which
the metabolic events of diabetes downregulate osteoblast function,
which in turn leads to less secretion of osteocalcin and a greater
aggravation of insulin resistance. However, results from human
studies have been inconsistent and often have implicated total
osteocalcin association with insulin sensitivity adipokines and inflam-
matory markers.19
This study was undertaken to compare the blood level of Glu‐OC
and Gla‐OC in nonobese, obese (prediabetic) and healthy obese (with-
out biochemical parameters' pathology) volunteers and correlate them
with the metabolic markers of insulin resistance and early markers of
inflammation.2 | MATERIALS AND METHODS
2.1 | Subjects and anthropometry
The study protocol and the entire study were approved by the Bioeth-
ics Committee of the Jagiellonian University in Cracow (writtenconsent, opinion no. KBET/82/B/2009) functioning according to the
third edition of the Guidelines on the Practice of Ethical Committees in
Medical Research issued by the Royal College of Physicians of London.
All participants gave written informed consent prior to participation in
the study. Consent was obtained from each subject after full explana-
tion of the purpose and nature of all used procedures. The study was
conducted in accordance with the Code of Ethics of theWorld Medical
Association (Declaration of Helsinki).
Obese (30 <body mass index [BMI] <40 kg/m2, n = 98) and
nonobese (BMI <30 kg/m2, n = 34) women and men, aged 25 to
65 years were included into the study. The exclusion criteria were con-
ditions that might affect the metabolic parameters and response to
diet such as: chronic diseases (cardiovascular diseases, cancer, chronic
inflammation), diabetes mellitus and other metabolic disorders, severe
kidney or liver failure, dietary restrictions or supplementation with:
vitamins, β‐carotene or n‐3 polyunsaturated fatty acids, therapy with:
hormones, anti‐inflammatory drugs or other drugs known to affect
lipid or glucose metabolism, smoking or excessive use of alcohol, preg-
nancy or lactation. All patients enrolled into this study were asked to
follow an isocaloric diet with a low amount of antioxidative vitamins,
polyunsaturated fatty acids and alcohol for 2 weeks before and during
the study. The diet instructions were presented to each patient and
diet compliance was controlled every 2 weeks by a dietitian.
Body weight was measured to the nearest 0.1 kg with a digital
scale, and height was measured to the nearest 0.5 cm using a wall‐
monitored stadiometer. Waist and hip circumferences were obtained
with a tape measure. Body composition was estimated with the
bioelectrical impedance method using Segmental Body Composition
Analyser TANITA BC 418 MA (Tanita, Japan). Blood pressure was
measured in the supine position after 10 minutes of rest with an
automatically inflating cuff.2.2 | Sample collection and analysis
After 2 weeks of diet standardization, venous blood samples were
drawn after 12 hours overnight fasting for measurements of basal
plasma Gla‐OC, Glu‐OC, total cholesterol, low‐density lipoprotein
(LDL) cholesterol, high‐density lipoprotein (HDL) cholesterol, TGs,
hsCRP, interleukin 6 (IL‐6) and soluble adhesion molecules: E‐selectin
(sE‐selectin), monocyte chemoattractant protein 1 (MCP‐1), soluble
platelet/endothelial cell adhesion molecule 1 (sPECAM‐1/CD31),
vascular cell adhesion protein 1 (sVCAM‐1) and adipokines (leptin,
adiponectin, visfatin, and resistin). To control kidney function,
estimated glomerular filtration rate (eGFR) was calculated using the
MDRD equation.
On 2 other different days, subjects underwent a 2‐hour oral
glucose tolerance test (OGTT) and an 8‐hour oral lipid tolerance test
(OLTT). Fasting and postprandial blood samples were drawn for OGTT
and OLTT and analyzed for concentrations of glucose, insulin, free
fatty acids (FFAs), TGs and glucose‐dependent insulinotropic polypep-
tide (GIP). Blood was sampled without stasis through an indwelling
catheter into syringes. Within 30 minutes, blood samples for all esti-
mated parameters (except FFAs) were centrifuged at 1000x g for
10 minutes at 4°C, and the supernatants were immediately stored at
−80°C until analysis.
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(WHO) and International Diabetes Federation (IDF) guidelines. Tests
were performed during morning hours (8:00–11:00 AM) after a 10‐
hour overnight fasting. Blood samples were collected at the following
5 time points: baseline (fasting), and then 30, 60, 90 and 120 minutes
after the ingestion of 75 g glucose dissolved in 250 mL water.
OLTTwas performed as described before.20 All patients were asked
not to drink alcohol or drinks containing caffeine for 3 days before the
test. The day before the OLTT, a last low‐fat meal was eaten by the
participants before 6 PM (2 slices of bread without any fatty products
and unsweetened tea). Only water was allowed to drink thereafter. Test
breakfasts were given at 7:30 AM, and postprandial studies were
performed from 7:30 AM to 5:30 PM. Test breakfast meal (caloric content
1018 kcal, consisting of: 73% of fat, 16% of protein and 11% of
carbohydrates) contained: light bread − 50 g, butter − 20 g, cream
cheese − 60 g, pork loin roast − 100 g and mayonnaise − 40 g. Venous
blood samples were taken 5 times before the meal (fasting sample,
0 hours) and postprandial at time points: 2, 4, 6 and 8 hours after
breakfast.2.3 | Blood analyses
Plasma Gla‐OC and Glu‐OC were determined by ELISA (Takara, Japan).
Intra‐ and interassay coefficients of variation were: <4.8% and <2.4%
(Gla‐OC), <6.66%, and <9.87% (Glu‐OC), respectively. Total
osteocalcin level was calculated as the sum of Gla‐OC and Glu‐OC.
Plasma glucose, total cholesterol, HDL cholesterol, and TGs were
assayed by automated, enzymatic colorimetric methods (Allmed,
Poland) using the MaxMat Analyzer. The intra‐ and interassay variabil-
ity coefficients were as follows: 2.3% and 3.5% (glucose), 1.4% and
3.4% (TGs), 1.4% and 3.8% (total cholesterol), 2.1% and 2.8% (HDL
cholesterol), respectively. LDL cholesterol was calculated from mea-
sured values of total cholesterol, TGs, and HDL cholesterol according
to the Friedewald formula.
FFAs concentration was measured immediately in non frozen
plasma by enzymatic quantitative colorimetric method (Roche
Diagnostics GmbH, Germany).
The determination of serum insulin was performed by
immunoradiometric method (DIAsource, ImmunoAssays, Belgium)
and read using the gamma counter (LKB Instruments). Within‐ and
between‐run imprecision CVs were 2.1% and 6.5%, respectively. Basal
insulin resistance was estimated using homeostasis model of assess-
ment (HOMA‐IR).21 Insulin sensitivity post oral glucose load was deter-
mined using an oral glucose insulin sensitivity index (OGIS) proposed
by Mari et al,22 which can be downloaded as a calculator for Excel
spread sheets from the web page http://webmet.pd.cnr.it/ogis.
To measure plasma concentrations of incretin—glucose dependent
insulinotropic polypeptide (GIP), human GIP ELISA (Human Total GIP;
EMD Millipore, St Charles, MO) was used. The inter‐ and intra‐assay
coefficients of variation were: 1.8% to 6.1% and 3.0% to 8.8%,
respectively.
Plasma leptin, adiponectin (adipocyte complement‐related protein
of 30 kDa, Acrp 30), resistin, IL‐6, sE‐Selectin, MCP‐1, and sVCAM‐1
were determined using ELISA (R&D Systems Europe, Ltd, Abingdon,
United Kingdom). Within‐ and between‐run imprecision CVs were3% and 4% (leptin), 4% and 6% (adiponectin), 5.3% and 8.2% (resistin),
6% and 7% (IL‐6), 6% and 8% (sE‐Selectin), 5% and 6% (MCP‐1), and
3.5% and 7.7% (sVCAM‐1), respectively. Visfatin (Nampt/PBEF) and
sPECAM‐1/CD31 were measured by ELISA (BioVendor, Czech
Republic). The inter‐ and intra‐assay CVs were 6% and 7% (visfatin),
1.7% and 7.4% (sPECAM‐1), respectively. CRP was determined by
the highly sensitive immunoturbidimetric method (APTEC Diagnostics
nv, Belgium). Within‐ and between‐run imprecision CVs were 1.66%
and 2.08%, respectively.2.4 | Statistical analyses
The Shapiro‐Wilk test was used to test data for a Gaussian distribution.
Normally distributed data are presented as mean ± SEM otherwise as
median and interquartile range (IQR). Differences between the main
studied groups (obese vs nonobese) and the formed subgroups were
analyzed by unpaired t test, the Mann‐Whitney U test, or the
Kruskal‐Wallis test and the Dunn test (comparison of results between
multiple groups) for nonnormally distributed data. Continuous vari-
ables were log transformed if required. The Spearman rank correlation
was used to find association between variables. All analyses were
performed with Statistica software (StatSoft). The P < .05 was consid-
ered statistically significant. Areas under curves (AUC) during OGTT or
OLTT were calculated by the trapezoidal method.233 | RESULTS
The characteristics of the study population of nonobese and obese
participants is presented in Tables 1 and 2. Obese volunteers (n = 98)
differ from nonobese ones (n = 34) in regard to anthropometric mea-
surements: BMI (34.0 vs 28.4 kg/m2, P < .001), adipose tissue mass
(40.8% vs 35.0%, P < .001), and blood pressure (Table 1). Patients with
higher BMI also showed increased plasma leptin levels and fasting
insulin. Area under the OGTT and OLTT insulin concentration‐time
curve and basal insulin resistance index HOMA‐IR were also increased
in obese patients (Table 2). Subjects in both groups participating in the
study did not differ in: plasma fasting and postprandial lipid levels (total
cholesterol, LDL cholesterol, HDL cholesterol, TGs, and FFAs) as well
as GIP levels.
Serum hsCRP and IL‐6 were higher in obese subjects. Plasma
levels of ALT, AST, urea, and uric acid were also elevated in this group
of patients (Tables 1 and 2). In the whole group of obese patients in
comparison to nonobese subjects, the level of Gla‐OCwas significantly
lower, whereas there were no significant differences in total
osteocalcin as well as Glu‐OC content (Table 2). For further analysis,
the whole group of study participants (n = 132) was divided into 2
groups (Table 3) or 4 groups (Table 4) in accordance to the higher
Gla‐OC (>11.2 ng/mL) and the lower Gla‐OC (<11.2 ng/mL) level
based on the median value. We observed that the group with
lower Gla‐OC level (n = 66) demonstrated a lower amount of Glu‐
OC, and Gla/Glu ratio, which was accompanied by higher blood
concentrations of inflammatory cytokines: hsCRP and visfatin. In
this group of patients, lower levels of total and LDL cholesterol,
sPECAM‐1, urea, creatinine and higher eGFR were observed in
TABLE 1 Characteristics of subjects participating in the study (anthropometric, biochemical, and lipid measurements)
Nonobese (n = 34) Obese (n = 98) P*
Age, y 48.05 ± 1.94 46.74 ± 1.15 n.s.
Sex, female (n) 27 72,00 n.s.
BMI, kg/m2 28.4 (2.2)† 34 (12.8) .000
WHR 0.87 (0.53) 0.89 (0.26) .537
Adipose tissue mass, % 35.0 (6.4) 40.8 (11.3) .000
Systolic BP, mm Hg 120 (24) 130 (52) .020
Diastolic BP, mm Hg) 80 (28) 85 (23) .010
APTT, s 29 (6.4) 29.0 (15.3) .908
Urea, mmol/L 4.4 (4.1) 5.0 (3.2) .030
Uric acid, mmol/L 240 (227.5) 302 (191.9) .020
ALT, U/L 17 (39) 24 (60) .001
AST, U/L 18 (12) 20 (45) .030
Total bilirubin, mmol/L 9.80 (21.5) 8.6 (12.4) .195
Creatinine, mmol/L 61.4 (36.5) 65.3 (31.1) .235
MDRD 91.8 (26.5) 91.4 (43.8) .621
Total cholesterol, mmol/L 5.38 ± 0.15‡ 5.54 ± 0.11 .986
HDL cholesterol, mmol/L 1.30 ± 0.03 1.31 ± 0.02 .997
LDL cholesterol, mmol/L 3.49 ± 0.14 3.55 ± 0.09 .765
Fasting NEFA, mmol/L 0.69 ± 0.03 0.76 ± 0.02 .141
AUC OGTT NEFA, mmol·L−1·min−1 155.24 ± 10.03 174.76 ± 8.56 .152
AUC OLTT NEFA, mmol·L−1·min−1 1546.02 ± 88.92 1554.73 ± 50.68 .429
Fasting triglycerides, mmol/L 1.31 ± 0.11 1.51 ± 0.07 .201
AUC OGTT triglycerides, mmol·L−1·min−1 615.98 ± 61.81 682.58 ± 33.11 .508
AUC OLTT triglycerides, mmol·L−1·min−1 3597.52 ± 374.66 3924.56 ± 193.02 .424
Selection of 2 subgroups: nonobese and obese participants. ALT indicates alanine transaminase; APTT, activated partial thromboplastin time; ASP, aspartate
transaminase; AUC, area under the curve; BMI, body mass index; BP, blood pressure; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; MDRD, an
estimated Glomerular Filtration Rate (eGFR) calculated from serum creatinine using the Modification of Diet in Renal Disease; NEFA, nonesterified fatty
acids; OGTT, oral glucose tolerance test; OLTT, oral lipid tolerance test; WHR, waist‐to‐hip ratio.
*Significant difference between nonobese and obese group (unpaired t test or Mann‐Whitney U test for nonnormally distributed variables), P < .05.
†Median (interquartile range); all such values.
‡Mean ± SEM; all such values.
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(Table 3). A weak negative correlation of Gla‐OC with: hsCRP
(r = −0.18, P = .042), visfatin concentration (r = −0.19, P = .033),
BMI (r = −0.17, P = .047) and eGFR (r = −0.31, P = .000) was found
(Table 5). No correlation of Gla‐OC with insulin resistance parameters
(fasting Insulin, HOMA‐IR or glucose levels) was found (Table 5). On
the contrary, Glu‐OC inversely correlated with fasting insulin level
and HOMA IR index (Table 5). Comparison of nonobese and obese
subjects regarding Gla‐OC levels (Table 4) showed that obese
patients with Gla‐OC >11.2 ng/mL presented higher Glu‐OC, total
and LDL cholesterol as well as sPECAM‐1 level than obese ones with
Gla‐OC <11.2 ng/mL. Such results were not observed in the group of
nonobese subjects (Table 4). Obese subjects with a Gla‐OC level less
than 11.2 ng/mL demonstrated higher plasma hsCRP level than
nonobese ones. Therefore, for further analysis, the group of obese
subjects was divided in accordance to metabolic disturbances. We
selected healthy obese subjects (without any metabolic disturbances)
(n = 29) and obese patients presenting symptoms of prediabetes with
or without atherogenic dyslipidemia (n = 32). The group with predia-
betes included subjects whose fasting plasma glucose was ≥5.6 and
<7.0 mmol/L or the level of glucose at the 2 hours of OGTT wasbetween 7.8 and 11 mmol/L. Lipid disturbances were considered when
serum fasting TG level was ≥1.7 mmol/L or the HDL cholesterol concen-
tration in men was <1.03 mmol/L and in women <1.29 mmol/L (Table 6).
Healthy obese volunteers presented higher Glu‐OC level than
those from the obese group with prediabetic disturbances (Table 6).
Insulin resistance symptoms (glucose, insulin, and HOMA‐IR) as well
as GIP levels were significantly higher in volunteers with prediabetes
(Table 6). The segregation of all obese subjects (n = 98) into 2 subgroups
based on Glu‐OC level (Glu‐OC<2.97 ng/mL and Glu‐OC>2.97 ng/mL)
revealed that subjects with lower levels of undercarboxylated
osteocalcin (n = 49) demonstrated increased fasting insulin levels and
insulin resistance indexHOMAIR (Table7), pointing todecreased insulin
sensitivity. On the contrary, no elevation of the investigated biochemi-
cal markers of inflammation was found in this group (Table 7).
Thus, the lower level of Glu‐OC in obese subjects characterized
the subjects with insulin resistance expressed by the increased fasting
plasma insulin and HOMA‐IR values, whereas the Gla‐OC level corre-
lated with the markers of inflammatory status indicated in our study
by the elevation of blood hsCRP and visfatin level.
Gla‐OC/Glu‐OC ratio had a tendency to distinguish obese healthy
individuals from prediabetic subjects (Table 6). The Gla‐OC/Glu‐OC
TABLE 2 Characteristics of subjects participating in the study (insulin sensitivity, inflammatory, and osteocalcin measurements)
Nonobese (n = 34) Obese (n = 98) P*
AUC OGTT Glucose, mmol·L−1·min−1 3378 (2564.5)† 3456 (1957) .250
AUC OLTT Glucose, mmol·L−1·min−1 9252 (2265) 9660 (2341.2) .140
AUC OGTT Insulin, mIU·mL−1·min−1 36609.93 ± 6199.96‡ 48561.10 ± 2745.49 .004
AUC OLTT Insulin, mIU·mL−1·min−1 31008 (122556) 42528 (110166) .001
Fasting GIP, pg/mL 23.3 (43.4) 26.1 (106.3) .199
AUC OGTT GIP, pg·mL−1·min−1 70796.84 ± 6411.65 71573.00 ± 2859.29 .480
AUC OLTT GIP, pg·mL−1·min−1 394982.14 ± 34515.85 365472.83 ± 14362.21 .350
Fasting glucose, mmol/L 5.22 ± 0.08 5.24 ± 0.05 .488
Fasting insulin, mIU/mL 12.49 ± 1.48 16.72 ± 0.78 .000
HOMA‐IR 2.06 (8.06) 3.45 (7.28) .000
OGIS, mL·min−1·m−2 387.11 ± 15.12 370.79 ± 7.65 .056
sE‐Selectin, pg/mL 32.95 (46.23) 37.23 (47.45) .073
MCP‐1, pg/mL 357.31 ± 16.85 366.58 ± 11.61 .310
sVCAM‐1, ng/mL 588.56 ± 22.37 590.81 ± 16.54 .548
sPECAM‐1, ng/mL 67.46 ± 2.91 72.43 ± 1.69 .634
hs CRP, mg/L 0.80 (5.75) 2.22 (8.41) .001
IL‐6, pg/mL 1.07 ± 0.12 1.63 ± 0.10 .001
IL‐8, pg/mL 2.13 (15.67) 2.21 (11.32) .767
TNF‐α, pg/mL 4.8 (11.4) 5.94 (9.22) .096
Leptin, pg/mL 27797.14 ± 1742.16 40657.72 ± 2438.83 .000
Adiponectin, ng/mL 6719 (8912) 6138 (12982) .441
Resistin, ng/mL 9.78 ± 0.52 10.11 ± 0.40 .730
Visfatin, ng/mL 1.09 ± 0.16 1.17 ± 0.08 .237
Total OC, ng/mL 15.92 ± 0.96 15.17 ± 0.47 .100
Gla‐OC, ng/mL 12.68 ± 0.90 11.36 ± 0.39 .048
Glu‐OC, ng/mL 3.23 ± 0.34 3.80 ± 0.24 .955
Gla‐OC/Glu‐OC, ng/mL 5.68 ± 0.81 3.83 ± 0.22 .281
Selection of 2 subgroups: nonobese and obese participants. AUC indicates area under the curve; GIP, glucose‐dependent insulinotropic peptide; Gla‐OC,
carboxylated osteocalcin; Glu‐OC, undercarboxylated osteocalcin; HOMA‐IR, homeostatic model assessment; hsCRP, high‐sensitivity C‐reactive protein;
IL‐6, interleukin 6; IL‐8, interleukin 8; MCP‐1, monocyte chemoattractant protein 1; OC, osteocalcin; OGIS, oral glucose insulin sensitivity index; OGTT, oral
glucose tolerance test; OLTT, oral lipid tolerance test; sPECAM‐1, soluble platelet/endothelial cell adhesion molecule 1; sVCAM‐1, vascular cell adhesion
protein 1, TNF‐α, tumor necrosis factor α.
*Significant difference between nonobese and obese group (unpaired t test or Mann‐Whitney U test for nonnormally distributed variables), P < .05.
†Median (interquartile range); all such values.
‡Mean ± SEM; all such values.
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obese subjects, negatively with inflammatory markers (hsCRP and
sVCAM) in obese prediabetic participants, and inversely with sE‐
selectin in nonobese patients (Table 8).
4 | DISCUSSION
Our study, performed on a healthy nonobese control group and obese
patients, demonstrated that despite a similar total osteocalcin level in
blood, a significantly lower concentration of Gla‐OC was found in
obese patients compared with nonobese subjects. The decreased con-
centration of Glu‐OC measured in the serum of obese patients charac-
terized subjects with insulin resistance expressed by the increased:
fasting insulin and glucose levels, postprandial (OLTT and OGTT
AUC) glucose concentration, higher HOMA‐IR value and with the
decrease in the osteocalcin. The Gla‐OC concentration was decreasedin patients with obesity and was associated with greater levels of the
inflammatory markers: hsCRP and visfatin24 as well as the E‐selectin
and s‐VCAM, which are markers of endothelial injury. Of note, no cor-
relation of osteocalcin forms with leptin, adiponectin or resistin was
observed in our group of obese volunteers.
Our findings confirmed that osteocalcin is an osteoblast‐specific
secreted protein, which participates not only in bone remodeling but
also in metabolism regulation. Bone remodeling is highly dependent
on the energetic status of the organism. For example, anorexia nervosa
and insulin‐dependent diabetes mellitus are associated with osteopo-
rosis, while a higher BMI is associated with increased bone mass.25
The hormones implicated in the regulation of food intake and energy
metabolism (ie, leptin, adiponectin and incretins) also regulate bone
mass.26–28
High‐fat diet (HFD) induces insulin resistance in osteoblasts and
leads to a decrease in circulating levels of the active form of
TABLE 3 Comparisons of 2 subgroups with a higher and lower than median value of Gla‐OC levels selected from the whole group of participating
subjects
Gla‐OC >11.2 ng/mL (n = 66) Gla‐OC <11.2 ng/mL (n = 66) P*
Gla‐OC, ng/mL 14.99 ± 0.45† 8.46 ± 0.2 .000
Glu‐OC, ng/mL 4.05 ± 0.24 3.3 ± 0.31 .008
Gla‐OC/Glu‐OC 5.02 ± 0.48 3.52 ± 0.23 .004
Total Osteocalcin, ng/mL 19.04 ± 0.47 11.78 ± 0.37 .000
Total Cholesterol, mmol/L 5.71 ± 0.12 5.28 ± 0.13 .014
LDL Cholesterol, mmol/L 3.78 ± 0.11 3.27 ± 0.10 .001
sPECAM‐1, ng/mL 74.45 ± 2.03 67.4 ± 2.05 .012
Visfatin, ng/mL 0.95 ± 0.09 1.34 ± 0.12 .038
hsCRP, mg/L 1.14 (9.18)‡ 2.61 (6.93) .046
Urea, mmol/L 5.1 (3.3) 4.6 (2.7) .024
Creatinine, mmol/L 66.3 (27.9) 63.3 (40.0) .02
MDRD 88.9 (38.8) 94.5 (51.1) .036
The calculated median was considered. Gla‐OC, indicates carboxylated osteocalcin; Glu‐OC, undercarboxylated osteocalcin; hsCRP, high‐ sensitivity
C reactive protein; MDRD, an estimated Glomerular Filtration Rate (eGFR) calculated from serum creatinine using the Modification of Diet in Renal Disease;
sPECAM‐1, soluble platelet/ endothelial cell adhesion molecule 1; LDL, low‐ density lipoprotein.
*Significant difference between Gla‐OC groups (unpaired t test or Mann‐Whitney U test for nonnormally distributed variables), P <0.05.
†Mean ± SEM; all such values.
‡Median (interquartile range); all such values.
TABLE 4 Comparisons of subgroups with a higher and lower than median value of Gla‐OC levels selected from nonobese and obese subjects
Nonobese (n = 34) Obese (n = 98)
P* P†
Gla‐OC <11.2 ng/mL
(n = 13)
Gla‐OC >11.2 ng/mL
(n = 21)
Gla‐OC <11.2 ng/mL
(n = 53)
Gla‐OC >11.2 ng/mL
(n = 45) Pa
Gla‐OC, ng/mL 8.32 (2.17) 15.14 (4.55)a 8.68 (2.30) 13.52 (2.96)b .000 P = .000a,
P = .000b
Glu‐OC, ng/mL 2.57 (0.48) 3.81 (2.88) 2.46 (1.74) 3.78 (2.89)b .0179 P = .0126b
Gla‐OC/Glu‐OC 3.37 (1.28) 3.98 (4.15) 3.43 (3.05) 3.60 (3.02) .0866 N/A
Total Osteocalcin,
ng/mL
11.85 (2.60) 19.59 (5.01)a 11.60 (3.06) 18.01 (3.39)b .000 P = .000a,
P = .000b
Total Cholesterol,
mmol/L
4.89 (1.02) 5.68 (1.28) 5.10 (0.98) 5.52 (1.46)b .0623 N/A
LDL Cholesterol,
mmol/L
3.20 (0.45) 4.07 (1.65) 3.25 (1.22) 3.78 (1.13)b .0108 P = .0226b
sPECAM‐1, ng/mL 68.25 (18.70) 72.78 (20.49) 64.68 (19.29) 81.01 (22.67)b .0215 P = .0292b
Visfatin, ng/mL 0.86 (0.85) 0.64 (0.49) 1.11 (0.99)c 0.80 (0.63) .0332 P = .0433c
hsCRP, mg/L 0.68 (0.84) 0.84 (1.06) 2.96 (3.54)d 1.48 (2.36) .0016 P = .0215d
Urea, mmol/L 3.90 (0.93) 4.80 (1.80) 4.85 (1.68) 5.40 (1.40)e .0104 P = .0049e
Creatinine, mmol/L 60.95 (6.55) 62.80 (9.90) 64.10 (10.15) 67.30 (8.25) .1039 N/A
MDRD 93.97 (8.15) 88.89 (18.38) 94.59 (19.61) 88.86 (19.41) .1326 N/A
The calculated median was considered. Gla‐OC indicates carboxylated osteocalcin; Glu‐OC, undercarboxylated osteocalcin; hsCRP, high‐sensitivity
C‐reactive protein; MDRD, an estimated Glomerular Filtration Rate (eGFR) calculated from serum creatinine using the Modification of Diet in Renal
Disease; sPECAM‐1, soluble platelet/endothelial cell adhesion molecule 1; LDL, low‐density lipoprotein; N/A, not applicable.
All values presented as median (interquartile range).
*P value for Kruskal‐Wallis ANOVA by ranks test.
†Significant difference between groups (Dunn test), P < .05.
aSignificant difference between nonobese Gla‐OC subgroups.
bSignificant difference between obese Gla‐OC subgroups.
cSignificant difference between nonobese Gla‐OC >11.2 ng/mL and obese Gla‐OC <11.2 ng/mL subgroups.
dSignificant difference between nonobese and obese groups with Gla‐OC <11.2 ng/mL.
eSignificant difference between nonobese with Gla‐OC <11.2 ng/mL and obese with Gla‐OC >11.2 ng/mL subgroups.
6 of 11 RAZNY ET AL.osteocalcin (thereby decreasing insulin sensitivity in skeletal muscle
and WAT).29 Insulin resistance developed in osteoblasts is suggested
to be the result of increased levels of free saturated fatty acids, whichpromote SMURF1‐mediated insulin receptor (INSR) ubiquitination and
its subsequent degradation in osteoblasts.7 These experiments support
the notion that insulin resistance in bone contributes to the deleterious
TABLE 5 Spearman rank correlation between Gla‐OC, Glu‐OC, and
metabolic variables in the entire group of subjects participating in the
study (n = 132)
r P
Gla‐OC and BMI −0.17 .047
Gla‐OC and hsCRP −0.18 .042
Gla‐OC and visfatin −0.19 .033
Gla‐OC and total cholesterol 0.22 .011
Gla‐OC and LDL cholesterol 0.3 .000
Gla‐OC and urea 0.25 .004
Gla‐OC and creatinine 0.28 .002
Gla‐OC and MDRD −0.31 .000
Glu‐OC and fasting insulin −0.18 .049
Glu‐OC and HOMA‐IR −0.17 .058
Statistically significant correlations: P < .05. BMI indicates body mass index;
Gla‐OC, carboxylated osteocalcin; Glu‐OC, undercarboxylated osteocalcin;
HOMA‐IR, homeostatic model assessment; hsCRP, high‐sensitivity C‐
reactive protein; MDRD, an estimated Glomerular Filtration Rate (eGFR)
calculated from serum creatinine using the Modification of Diet in Renal
Disease; LDL, low‐density lipoprotein.
RAZNY ET AL. 7 of 11consequences of a long‐term HFD on whole‐body glucose homeosta-
sis, in part because it decreases the activity of osteocalcin.7
Osteocalcin is γ‐carboxylated on the glutamic acids (GLU) 13, 17,
and 20 of protein in mouse, and on GLU 17, 21, and 24 in humans.30
The carboxylation of osteocalcin and other Gla proteins occurs in
the lumen of the endoplasmic reticulum and involves 2 enzymes
γ‐glutamyl carboxylase and vitamin K epoxide reductase (VKORC1),TABLE 6 Comparison between the subgroup of obese patients without bi
patients with biochemical markers of metabolic syndrome (prediabetic pati
Obese healthy (n = 29)
WHR 0.84 (0.23)†
Fasting glucose, mmol/L 4.98 ± 0.06‡
Glucose OLTT AUC, mmol/L·min−1 3282 (1173)
Glucose OGTT AUC, mmol/L·min−1 9240 (2168)
Fasting Insulin, μIU/mL 13.11 ± 1.02
Fasting GIP, pg/mL 23.73 (73.50)
OGIS, mL·min−1·m−2 381.59 ± 12.83
HOMA‐IR 2.73 (4.69)
Fasting TG, mmol/L 0.98 ± 0.05
TG OLTT AUC, mmol·L−1·min−1 2676.09 ± 180.80
TG OGTT AUC, mmol·L−1·min−1 434.50 ± 25.16
HDL Cholesterol, mmol·L−1 1.47 ± 0.04
Total osteocalcin, ng/mL 15.94 ± 1.10
Gla‐OC, ng/mL 11.46 ± 0.86
Glu‐OC, ng/mL 4.48 ± 0.57
Gla‐OC/Glu‐OC ratio 3.60 ± 0.47
AUC indicates area under the curve; GIP, glucose‐dependent insulinotropic
osteocalcin; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model ass
tolerance test; OLTT, oral lipid tolerance test; TG, triglycerides; WHR, waist‐to‐
*Significant difference between obese healthy and obese prediabetic group (unp
P < .05.
†Median (interquartile range); all such values.
‡Mean ± SEM; all such values.which together constitute the vitamin K‐dependent cycle. This
posttranslational modification increases the affinity of osteocalcin
for Ca2+ and therefore for hydroxyapatite, the mineral component
of bone extracellular matrix (ECM). The vast majority of osteocalcin
secreted by osteoblasts gets trapped in bone ECM.30 In the serum,
both the carboxylated and the undercarboxylated forms of osteocalcin
are detected. The mechanism responsible for the differences in con-
centration and carboxylation status of osteocalcin has not yet been
precisely elucidated. Possible mechanisms include certain hormones
as well as both nutritional and non–nutritional‐related factors such
as: vitamin D, vitamin K or calcium.16 Complex carbohydrate meals
containing high amounts of fruits, vegetables and vitamins failed to sig-
nificantly affect circulating concentrations of postprandial osteocalcin.
Low as well as high carbohydrate meals resulted in decreased concen-
trations of osteocalcin over time. Henriksen et al31 showed that oral
ingestion of long chain triacylglycerides had no effect on osteocalcin
concentration.
In our studies, a decreased level of Gla‐OC in obese patients was
observed. The Gla‐OC concentration in serum inversely correlated
with markers associated with low‐grade inflammation in obesity:
hsCRP and visfatin. Our results are in agreement with in vitro studies,
which revealed anti‐inflammatory properties of osteocalcin. In experi-
ments conducted on primary‐cultured adipocytes, Hill et al15 showed
that both forms of osteocalcin suppressed the secretion of tumor
necrosis factor alpha into the media. However, only carboxylated
osteocalcin suppressed IL‐6 release. Both carboxylated and
uncarboxylated osteocalcin increased the secretion of adiponectinochemical markers of metabolic syndrome (“healthy obese”) and obese
ents)
Obese with metabolic disturbances
in prediabetes (n = 32) P*
0.92 (0.17) .044
5.69 ± 0.09 .000
4218 (1390) .000
10176 (1620) .000
19.11 ± 1.59 .001
32.80 (103.70) .044
327.94 ± 12.83 .005
4.48 (7.51) .000
1.53 ± 0.12 .000
4015.65 ± 305.51 .000
673.07 ± 51.75 .000
1.29 ± 0.06 .005
14.41 ± 0.72 .432
11.37 ± 0.59 .834
3.04 ± 0.28 .025
4.35 ± 0.32 .040
peptide; Gla‐OC, carboxylated osteocalcin; Glu‐OC, undercarboxylated
essment; OGIS, oral glucose insulin sensitivity index; OGTT, oral glucose
hip ratio.
aired t test or Mann‐Whitney U test for nonnormally distributed variables),
TABLE 7 Comparisons of 2 subgroups with a higher and lower than median value of Glu‐OC level selected from the obese group of participating
subjects
Obese (n = 98)
Glu‐OC >2.97 ng/mL (n = 49) Glu‐OC <2.97 ng/mL (n = 49) P*
Glu‐OC, ng/mL 5.35 ± 0.34† 2.08 ± 0.07 .000
Gla‐OC, ng/mL 11.55 ± 0.50 10.92 ± 0.60 .297
Total osteocalcin, ng/mL 16.91 ± 0.60 13.01 ± 0.63 .000
Fasting insulin, mIU/mL 15.46 ± 1.16 17.81 ± 1.02 .030
HOMA‐IR 2.96 (8.10)‡ 3.96 (5.21) .015
sE‐Selectin, pg/mL 38.34 (35.92) 33.61 (84.39) .260
hsCRP, mg/L 2.2 (8.10) 2.49 (7.90) .734
Visfatin, ng/mL 1.12 ± 0.11 1.25 ± 0.12 .054
IL‐6, pg/mL 1.50 ± 0.10 1.74 ± 0.18 .836
MCP‐1, pg/mL 371.47 ± 15.97 362.93 ± 17.09 .610
sVCAM‐1, ng/mL 624.90 ± 26.56 632.35 ± 24.48 .772
sPECAM‐1, ng/mL 72.83 ± 2.39 71.63 ± 2.40 .521
The calculated median was considered. Gla‐OC indicates carboxylated osteocalcin; Glu‐OC, undercarboxylated osteocalcin; HOMA‐IR, homeostatic model
assessment; hsCRP, high‐sensitivity C‐reactive protein; IL‐6, interleukin 6; MCP‐1, monocyte chemoattractant protein 1; sPECAM‐1, soluble platelet/
endothelial cell adhesion molecule 1; sVCAM‐1, vascular cell adhesion protein 1.
*Significant difference between Glu‐OC groups (unpaired t test or Mann‐Whitney U test for nonnormally distributed variables), P < .05.
†Mean ± SEM; all such values.
‡Median (interquartile range); all such values.
TABLE 8 Spearman rank correlation between Gla‐OC/Glu‐OC ratio values and biochemical variables in nonobese controls, obese, and obese with
biochemical markers of prediabetes
Spearman rank correlation Gla‐OC/Glu‐OC ratio
Nonobese (n = 34) Obese (n = 98) Obese with metabolic disturbances in prediabetes (n = 32)
r P* r P* r P*
Fasting insulin 0.09 .63 0.26 .01 0.09 .63
Fasting glucose −0.12 .51 0.11 .29 −0.05 .77
HOMA‐IR 0.09 .61 0.26 .01 0.02 .92
OGIS 0.33 .09 −0.06 .60 −0.12 .54
Total cholesterol 0.07 .68 0.05 .64 0.02 .89
HDL cholesterol 0.05 .80 −0.13 .21 −0.24 .19
LDL cholesterol 0.07 .67 0.12 .26 0.01 .97
TG 0.18 .32 −0.09 .38 −0.16 .37
sE‐Selectin −0.38 .03 −0.09 .39 −0.09 .63
hsCRP 0.20 .27 −0.12 .23 −0.38 .03
Visfatin −0.15 .39 0.03 .75 −0.24 .18
IL‐6 0.10 .56 −0.13 .21 −0.30 .10
MCP‐1 0.00 .99 0.04 .68 0.17 .38
sVCAM‐1 0.00 1.00 −0.07 .51 −0.41 .03
sPECAM‐1 0.18 .32 −0.02 .86 −0.09 .65
TNF‐α 0.02 .90 −0.02 .84 −0.07 .75
Gla‐OC indicates carboxylated osteocalcin; Glu‐OC, undercarboxylated osteocalcin; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model assess-
ment; hsCRP, high‐sensitivity C‐reactive protein; IL‐6, interleukin 6; LDL, low‐density lipoprotein; MCP‐1, monocyte chemoattractant protein 1;
sPECAM‐1, soluble platelet/endothelial cell adhesion molecule 1; sVCAM‐1, vascular cell adhesion protein 1, TG, triglycerides; TNF‐α, tumor necrosis
factor α.
*Significant Spearman rank correlation, P < .05.
8 of 11 RAZNY ET AL.and the anti‐inflammatory cytokine IL‐10. So far, human studies of the
association between osteocalcin and inflammatory factors are still
lacking. Although several human studies reported the inverse
association between serum osteocalcin (without distinguishingbetween Gla‐OC and Glu‐OC) and hsCRP,32–34 we are the first to
show this association for the carboxylated osteocalcin form.
However, the mechanism linking hsCRP and bone metabolism is
not well understood. The anti‐inflammatory effect of Gla‐OC could
RAZNY ET AL. 9 of 11be explained as a result of vitamin K action. It is well known that vita-
min K has anti‐inflammatory properties that could be mediated by car-
boxylated osteocalcin. On the other hand, an increase in systemic
inflammatory response could be connected with osteocalcin carboxyl-
ation defect as a result of lowered serum vitamin K level. However, a
recent study indicates anti‐inflammatory action of vitamin K indepen-
dently of osteocalcin carboxylation.35 As regards association between
visfatin and osteocalcin, Kacso et al36 reported a negative correlation
of Glu‐OCwith visfatin in type 2 diabetes patients with diabetic kidney
disease. In our studies, we observed an association of Gla‐OC but not
Glu‐OC with visfatin. However, subjects enrolled in our experiments
were obese but did not develop diabetes.
Most of the in vitro and in vivo studies conducted so far indicate
that osteocalcin endocrine function is regulated by its
undercarboxylated form.37,38 In contrast to Gla‐OC, Glu‐OC does not
bind Ca2+ and, more importantly, does not require elevated Ca2+ con-
centration to fold into a helical structure. These observations suggest
that at Ca2+ concentrations at approximately 1 mM, as normally found
in cell culture media or in vivo in serum, only Glu osteocalcin will
exhibit a helical conformation and presumably be able to activate its
receptor(s) (ie, GPRC6A), providing a structural explanation for the lack
of biological activity of Gla osteocalcin on glucose metabolism.39,40 It
acts on pancreatic β cells to increase insulin secretion, on muscle and
WAT to promote glucose uptake and homeostasis, and on Leydig cells
of the testis to favor testosterone biosynthesis after its binding to a
GPRC6A receptor.4,6,8,10,13,37 In animal models and in in vitro studies,
it has been demonstrated that recombinant osteocalcin regulates
insulin biosynthesis, by stimulation Ins1 and Ins2 gene expression in
pancreatic islets, and is also a potent insulin secretagogue because of
its ability to increase cytosolic Ca2+ levels.12,13,40,41 This mechanism
may contribute to the observed selected symptoms of insulin
resistance in obese patients in our human study.
Using an animal model of HFD‐fed mice, Wei et al7 determined
that the severity of glucose intolerance and insulin resistance is in part
a consequence of osteoblast‐dependent insulin resistance. In obese
individuals, total OC has been described to be associated with skeletal
muscle but not hepatic insulin sensitivity, whereas undercarboxylated
OC is uniquely associated with β‐cell function only in individuals with
impaired fasting glucose.42
Insulin resistance in osteoblasts led to a decrease in circulating
levels of the Glu‐OC observed in our human study, thereby decreasing
insulin sensitivity in skeletal muscle. The underlying mechanism is not
yet established, but besides promotion of insulin receptor
ubiquitination (observed increased activity of SMURF1) and subse-
quent degradation in the proteasome, other mechanisms are possible.
For example, the content in tissues of total diacylglycerols (DAGs), a
group of lipid intermediate metabolites thought to account for
lipotoxicity and insulin resistance, is significantly elevated under
obesity. DAGs activate several serine kinases, such as c‐Jun amino‐
terminal kinase, protein kinase C, and IκB kinase β (IKKβ), which
phosphorylates inhibitory serine residues of the insulin receptor and
insulin receptor substrates and thereby blocking insulin action.43 IKKβ
phosphorylation leads to the activation of nuclear factor‐κB–mediated
pathways, including the inflammatory one. These results underscore
the involvement of bone (among other tissues) in the disruption ofglucose homeostasis resulting from lipotoxicity and involvement of
insulin and osteocalcin cross talk in glucose intolerance.4,6–8,10,13,44
Along with this, is the recent demonstration that disrupting
osteocalcin signaling in humans leads to glucose intolerance. Using
mouse models, Oury et al found that osteocalcin and LH act in 2 parallel
pathways and that osteocalcin‐stimulated testosterone synthesis is pos-
itively regulated by bone resorption and insulin signaling in osteoblasts.10
In humans, they analyzed a cohort of patients with primary testicular
failure and identified 2 individuals harboring the same heterozygous
missense variant in one of the transmembrane domains of GPRC6A,
which prevented the receptor from localizing to the cell membrane. It
was a point mutation in exon 4 of GPRC6A, resulting in F464Y amino
acid substitution. This missense mutation affects a highly conserved
residue, occurring in one of the transmembrane regions of the molecule
and preventing its localization to the cell membrane, therefore resulting
in a loss of function of GPRC6A. Patients harboring this substitution‐
mutation demonstrated higher fasting insulin and glucose levels as well
as pathological OGTT parameters. Thus, insulin resistance in bone might
contribute to whole‐body insulin resistance in patients with type 2
diabetes.10 Interestingly, it has recently been determined that the known
detrimental effect of glucocorticoids on glucose metabolism could be in
part explained by its negative action on osteocalcin production.45 Recent
publications in mouse models suggest that the protective effect of
osteocalcin on obesity and insulin resistance might be, at least in part,
due to its capacity to increase adiponectin release and energy expendi-
ture in brown adipose tissue and skeletal muscle.12,13,15 As mentioned
previously, we did not observe any correlation between osteocalcin
forms and adiponectin. Similar to our results, Wang et al46 reported that
total osteocalcin inversely correlated with HbA1c, and Glu‐OC inversely
correlatedwith fasting blood glucose. However, no significant correlation
was found between osteocalcin and HOMA‐IR.
The implementation of the Gla/Glu or Glu‐OC/total OC ratio was
suggested for finding an association between Glu‐OC and metabolic
syndrome parameters in children.47 In our study, the presence of
biochemical markers of prediabetes resulted in an increase in the
Gla‐OC/Glu‐OC ratio value in comparison with healthy obese subjects.
Of note, the Gla/Glu ratio value correlated positively with insulin
resistance markers in obese patients and negatively with markers of
inflammation in nonobese controls and in obese patients with
metabolic disturbances.
However, the study has potential limitations, namely, an unequal
number of both sexes and the small number of subjects in the study.
Another limitation of the study is the small number of control group
participants in comparison to obese subjects. So far, osteocalcin
findings have shown that Glu‐OC and Gla‐OC are bystander markers
rather than mechanistic ones. Data from human studies concerning
these 2 markers are rather inconsistent, and their mechanism of
action is not fully understood. Therefore, we postulate that the results
of our study could be a base for further studies explaining the mecha-
nism of osteocalcin action in larger groups of subjects. Our results
argue for the suggestion that the decreased blood concentration of
Glu‐OC may be an early symptom of insulin resistance development
in obesity, whereas the decreased level of Gla‐OC seems to be
connected with early symptoms of obesity associated inflammation
in humans.
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